| 000 | 01849 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514160647.0 | ||
| 264 | 0 | _c20031120 | |
| 008 | 200311s 0 0 eng d | ||
| 022 | _a1055-3207 | ||
| 024 | 7 |
_a10.1016/s1055-3207(03)00036-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChauffert, Bruno | |
| 245 | 0 | 0 |
_aRationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. _h[electronic resource] |
| 260 |
_bSurgical oncology clinics of North America _cJul 2003 |
||
| 300 |
_a835-48 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacokinetics |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aCarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aEpinephrine _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Parenteral |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 650 | 0 | 4 |
_aPeritoneal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aTissue Distribution |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aFavoulet, Patrick | |
| 700 | 1 | _aPolycarpe, Emmanuel | |
| 700 | 1 | _aDuvillard, Christian | |
| 700 | 1 | _aBeltramo, Jean-Luc | |
| 700 | 1 | _aBichat, Francis | |
| 700 | 1 | _aRat, Patrick | |
| 700 | 1 | _aGenne, Philippe | |
| 700 | 1 | _aBenoit, Laurent | |
| 773 | 0 |
_tSurgical oncology clinics of North America _gvol. 12 _gno. 3 _gp. 835-48 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1055-3207(03)00036-x _zAvailable from publisher's website |
| 999 |
_c14309705 _d14309705 |
||